Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in Q2 2026Completed enrollment in the Phase 2/3 DRAGON II trial in STGD1Completed a $402 million underwritten public offering of American Depositary SharesConference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET SAN DIEGO, March 02, 2026 ( ...